Evidence map›Paper›PMID 39035166›Full record

ArticlePeerJ2024

Secretomic changes of amyloid beta peptides on Alzheimer's disease related proteins in differentiated human SH-SY5Y neuroblastoma cells.

Sittiruk Roytrakul, Janthima Jaresitthikunchai, Narumon Phaonakrop, Sawanya Charoenlappanit, Siriwan Thaisakun, Nitithorn Kumsri, Teerakul Arpornsuwan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sittiruk RoytrakulFunctional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, Thailand.
Janthima JaresitthikunchaiFunctional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, Thailand.
Narumon PhaonakropFunctional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, Thailand.
Sawanya CharoenlappanitFunctional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, Thailand.
Siriwan ThaisakunFunctional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, Thailand.
Nitithorn KumsriUndergraduate Student of Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand.
Teerakul ArpornsuwanMedical Technology Research and Service Unit, Health Care Service Center, Faculty of Allied Health Sciences, Thammasat University, Pathumthani, Thailand.

Funding

Royal Thai Government Grant supported by Thammasat UniversityThailand Science Research and Innovation (TSRI) Fundamental Fund fiscal year 2022
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that causes physical damage to neuronal connections, leading to brain atrophy. This disruption of synaptic connections results in mild to severe cognitive impairments. Unfortunately, no effective treatment is currently known to prevent or reverse the symptoms of AD. The aim of this study was to investigate the effects of three synthetic peptides, i.e., KLVFF, RGKLVFFGR and RIIGL, on an AD

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrain-Derived Neurotrophic FactorCell DifferentiationNeuroblastomatau ProteinsAmyloid beta-Protein PrecursorCell Line, TumorHumansTretinoinAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBrain-Derived Neurotrophic FactorMAPT protein, humantau ProteinsTretinoinAlzheimer’s diseaseAβ42: Aβ40 ratioBrain-derived neurotrophic factor (BDNF)Neuroblastoma (SH-SY5Y)Retinoic acid (RA)Shotgun proteomics

Identifiers

PMID39035166
PMCPMC11260076

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.